Order byBest matchMost fresh

Dr. Peter, FDA

Digest more
Top News
Impacts
The pharma industry, Wall Street and former government officials on Monday decried the forced resignation of FDA vaccine regulator Dr. Peter Marks, openly worrying that his exit portends an antiscien...
From Politico
RBC Capital analyst Brian Abrahams warned that Marks’ exit could lead to disruptions at the FDA, affecting drug approvals and regulatory flexibility.
From Business Insider

Read more on News Digest

The Peter Marks effect
The pharma industry, Wall Street and former government officials on Monday decried the forced resignation of FDA vaccine regulator Dr. Peter Marks, openly worrying that his exit portends an antiscience shift at the agency.
Why Peter Marks Was Asked to Leave the FDA
Dr. Peter Marks announced his resignation from the U.S. Food and Drug Administration (FDA) as Director of CEBR (Center for Biologics Evaluation and Research) citing differences with Health
Biotech Stocks Fall As FDA's Peter Marks Resigns
Vaccine and biotech stocks plummeted after Peter Marks, a top regulator at the US Food and Drug Administration, resigned due to friction with Health and Human Services Secretary Robert F. Kennedy Jr.
Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation and Research
Drugmakers sink after key FDA official ousted as Trump plans health overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official, Peter Marks, had been forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Biotech Investors Rush for the Exits After FDA Official Resigns
Biotech investors are reeling after the sudden departure of Peter Marks, a pivotal figure in the U.S. Food and Drug Administration. Marks, who played a crucial role in Operation Warp Speed and champio
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
Who Is Dr. Peter Marks? FDA’s Top Vaccine Official Quits, Citing RFK Jr.’s ‘Misinformation And Lies.’
Marks offered his resignation while citing Kennedy’s “misinformation and lies” and an “unprecedented assault on scientific truth” impacting public health.
Dr. Peter Marks, top vaccine official at FDA, resigns and criticizes RFK Jr.
Dr. Peter Marks, the top vaccine official at the Food and Drug Administration, wrote in a letter that he was resigning from his position.
Peter Marks, top FDA vaccine official, forced to resign
Dr. Peter Marks, the top vaccine regulator at the U.S. Food and Drug Administration, was forced to resign, citing Health and Human Services Secretary Robert F. Kennedy Jr.'s "misinformation and lies" around immunization.
Top vaccine official Peter Marks forced out at FDA, WSJ reports
The U.S. Food and Drug Administration's top vaccine official, Peter Marks, has been pushed out, the Wall Street Journal reported on Friday. Marks, who played a key role in U.S. President Donald Trump's first term in developing COVID-19 vaccines,
Explore more
STAT2d
FDA’s ‘key man’ Peter Marks is out. Biotech investors will now deal with the consequences
Peter Marks’ ouster comes at a time when the sector is already suffering through a years-long public markets slump.
STAT1d
Marks’ exit is not exactly helping industry sentiment
Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary Robert F. Kennedy Jr. on vaccines. Moderna’s stock dropped 9%, while Vaxcyte’s plummeted 46% (though shares of Vaxcyte were also affected by disappointing results of a vaccine candidate.)
Fierce Pharma2d
As FDA's Peter Marks resigns, industry watchers size up vaccine, cell and gene therapy hits
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency is heading for the exit. | In resigning as director of the FDA’s Center for Biologics Evaluation and Research,
BioSpace2d
Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down
The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, who said RFK Jr. does not seek “truth and transparency” but rather “subservient confirmation of his misinformation and lies.
Fierce Pharma1d
FDA's new commissioner Marty Makary signed off on Peter Marks ouster: Politico
It's not yet been a week since Marty Makary, M.D., was confirmed to lead the FDA as its commissioner. | Peter Marks, M.D., Ph.D., a target for RFK Jr. and allies, last week turned in his resignation as director of the FDA's Center for Biologics Evaluation and Research.
Feedback